Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials group 128)

Michael T. Brady, Nuala McGrath, Pim Brouwers, Richard Gelber, Mary Glenn Fowler, Ram Yogev, Nancy Hutton, Yvonne J. Bryson, Charles D Mitchell, Senih Fikrig, William Borkowsky, Eleanor Jimenez, George McSherry, Arye Rubinstein, Catherine M. Wilfert, Kenneth McIntosh, Mary Maha Elkins, Peggy S. Weintrub

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The current dosage of zidovudine for children is 180 mg/m2 every 6 h. To investigate whether a lower dosage was equally effective, human immunodeficiency virus (HIV)-infected children (3 months to 12 years) with mild to moderate symptoms were randomly assigned to receive either high-dose (180 mg/m2/dose) or low-dose (90 mg/m2/dose) zidovudine (double-blind). Treatments were compared with respect to neuropsychologic function, survival, clinical and laboratory evidence of disease progression, and safety and tolerance. Four hundred twenty-six HIV-infected children were enrolled; median time for receipt of study drug was 35 months. Zidovudine in either dose was well tolerated, with no difference in efficacy or tolerance by treatment group using any clinical or laboratory parameter. In children with mild to moderate disease, a reduction of zidovudine to 90 mg/m2/dose will result in substantial cost savings and should be the recommended dose.

Original languageEnglish
Pages (from-to)1097-1106
Number of pages10
JournalJournal of Infectious Diseases
Volume173
Issue number5
StatePublished - Aug 10 1996
Externally publishedYes

Fingerprint

Zidovudine
Acquired Immunodeficiency Syndrome
Clinical Trials
HIV
Cost Savings
Disease Progression
Safety
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials group 128). / Brady, Michael T.; McGrath, Nuala; Brouwers, Pim; Gelber, Richard; Fowler, Mary Glenn; Yogev, Ram; Hutton, Nancy; Bryson, Yvonne J.; Mitchell, Charles D; Fikrig, Senih; Borkowsky, William; Jimenez, Eleanor; McSherry, George; Rubinstein, Arye; Wilfert, Catherine M.; McIntosh, Kenneth; Elkins, Mary Maha; Weintrub, Peggy S.

In: Journal of Infectious Diseases, Vol. 173, No. 5, 10.08.1996, p. 1097-1106.

Research output: Contribution to journalArticle

Brady, MT, McGrath, N, Brouwers, P, Gelber, R, Fowler, MG, Yogev, R, Hutton, N, Bryson, YJ, Mitchell, CD, Fikrig, S, Borkowsky, W, Jimenez, E, McSherry, G, Rubinstein, A, Wilfert, CM, McIntosh, K, Elkins, MM & Weintrub, PS 1996, 'Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials group 128)', Journal of Infectious Diseases, vol. 173, no. 5, pp. 1097-1106.
Brady, Michael T. ; McGrath, Nuala ; Brouwers, Pim ; Gelber, Richard ; Fowler, Mary Glenn ; Yogev, Ram ; Hutton, Nancy ; Bryson, Yvonne J. ; Mitchell, Charles D ; Fikrig, Senih ; Borkowsky, William ; Jimenez, Eleanor ; McSherry, George ; Rubinstein, Arye ; Wilfert, Catherine M. ; McIntosh, Kenneth ; Elkins, Mary Maha ; Weintrub, Peggy S. / Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials group 128). In: Journal of Infectious Diseases. 1996 ; Vol. 173, No. 5. pp. 1097-1106.
@article{e8be8333573347a8b95ef286a1789816,
title = "Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials group 128)",
abstract = "The current dosage of zidovudine for children is 180 mg/m2 every 6 h. To investigate whether a lower dosage was equally effective, human immunodeficiency virus (HIV)-infected children (3 months to 12 years) with mild to moderate symptoms were randomly assigned to receive either high-dose (180 mg/m2/dose) or low-dose (90 mg/m2/dose) zidovudine (double-blind). Treatments were compared with respect to neuropsychologic function, survival, clinical and laboratory evidence of disease progression, and safety and tolerance. Four hundred twenty-six HIV-infected children were enrolled; median time for receipt of study drug was 35 months. Zidovudine in either dose was well tolerated, with no difference in efficacy or tolerance by treatment group using any clinical or laboratory parameter. In children with mild to moderate disease, a reduction of zidovudine to 90 mg/m2/dose will result in substantial cost savings and should be the recommended dose.",
author = "Brady, {Michael T.} and Nuala McGrath and Pim Brouwers and Richard Gelber and Fowler, {Mary Glenn} and Ram Yogev and Nancy Hutton and Bryson, {Yvonne J.} and Mitchell, {Charles D} and Senih Fikrig and William Borkowsky and Eleanor Jimenez and George McSherry and Arye Rubinstein and Wilfert, {Catherine M.} and Kenneth McIntosh and Elkins, {Mary Maha} and Weintrub, {Peggy S.}",
year = "1996",
month = "8",
day = "10",
language = "English",
volume = "173",
pages = "1097--1106",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials group 128)

AU - Brady, Michael T.

AU - McGrath, Nuala

AU - Brouwers, Pim

AU - Gelber, Richard

AU - Fowler, Mary Glenn

AU - Yogev, Ram

AU - Hutton, Nancy

AU - Bryson, Yvonne J.

AU - Mitchell, Charles D

AU - Fikrig, Senih

AU - Borkowsky, William

AU - Jimenez, Eleanor

AU - McSherry, George

AU - Rubinstein, Arye

AU - Wilfert, Catherine M.

AU - McIntosh, Kenneth

AU - Elkins, Mary Maha

AU - Weintrub, Peggy S.

PY - 1996/8/10

Y1 - 1996/8/10

N2 - The current dosage of zidovudine for children is 180 mg/m2 every 6 h. To investigate whether a lower dosage was equally effective, human immunodeficiency virus (HIV)-infected children (3 months to 12 years) with mild to moderate symptoms were randomly assigned to receive either high-dose (180 mg/m2/dose) or low-dose (90 mg/m2/dose) zidovudine (double-blind). Treatments were compared with respect to neuropsychologic function, survival, clinical and laboratory evidence of disease progression, and safety and tolerance. Four hundred twenty-six HIV-infected children were enrolled; median time for receipt of study drug was 35 months. Zidovudine in either dose was well tolerated, with no difference in efficacy or tolerance by treatment group using any clinical or laboratory parameter. In children with mild to moderate disease, a reduction of zidovudine to 90 mg/m2/dose will result in substantial cost savings and should be the recommended dose.

AB - The current dosage of zidovudine for children is 180 mg/m2 every 6 h. To investigate whether a lower dosage was equally effective, human immunodeficiency virus (HIV)-infected children (3 months to 12 years) with mild to moderate symptoms were randomly assigned to receive either high-dose (180 mg/m2/dose) or low-dose (90 mg/m2/dose) zidovudine (double-blind). Treatments were compared with respect to neuropsychologic function, survival, clinical and laboratory evidence of disease progression, and safety and tolerance. Four hundred twenty-six HIV-infected children were enrolled; median time for receipt of study drug was 35 months. Zidovudine in either dose was well tolerated, with no difference in efficacy or tolerance by treatment group using any clinical or laboratory parameter. In children with mild to moderate disease, a reduction of zidovudine to 90 mg/m2/dose will result in substantial cost savings and should be the recommended dose.

UR - http://www.scopus.com/inward/record.url?scp=8944262046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944262046&partnerID=8YFLogxK

M3 - Article

VL - 173

SP - 1097

EP - 1106

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -